Abeona Therapeutics Statistics

Total Valuation

Abeona Therapeutics has a market cap or net worth of GBP 193.75 million. The enterprise value is 124.09 million.

Market Cap	193.75M
Enterprise Value	124.09M

Important Dates

The next estimated earnings date is Wednesday, March 26, 2025.

Earnings Date	Mar 26, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+92.79%
Shares Change (QoQ)	-6.14%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	27.85M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	5.67
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-2.34
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-3.29

Financial Position

The company has a current ratio of 6.12, with a Debt / Equity ratio of 0.50.

Current Ratio	6.12
Quick Ratio	6.04
Debt / Equity	0.50
Debt / EBITDA	n/a
Debt / FCF	-0.46
Interest Coverage	-18.78

Financial Efficiency

Return on equity (ROE) is -209.50% and return on invested capital (ROIC) is -78.60%.

Return on Equity (ROE)	-209.50%
Return on Assets (ROA)	-40.68%
Return on Invested Capital (ROIC)	-78.60%
Return on Capital Employed (ROCE)	-59.46%
Revenue Per Employee	n/a
Profits Per Employee	-630,916
Employee Count	84
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +19.11% in the last 52 weeks. The beta is 1.51, so Abeona Therapeutics's price volatility has been higher than the market average.

Beta (5Y)	1.51
52-Week Price Change	+19.11%
50-Day Moving Average	5.74
200-Day Moving Average	5.50
Relative Strength Index (RSI)	52.62
Average Volume (20 Days)	1,407

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	9.57

Income Statement

Revenue	n/a
Gross Profit	-23.43M
Operating Income	-45.32M
Pretax Income	-53.00M
Net Income	-53.00M
EBITDA	-43.86M
EBIT	-45.32M
Earnings Per Share (EPS)	-1.50

Full Income Statement

Balance Sheet

The company has 81.85 million in cash and 17.24 million in debt, giving a net cash position of 64.61 million.

Cash & Cash Equivalents	81.85M
Total Debt	17.24M
Net Cash	64.61M
Net Cash Per Share	n/a
Equity (Book Value)	34.15M
Book Value Per Share	0.79
Working Capital	70.31M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -36.33 million and capital expenditures -1.40 million, giving a free cash flow of -37.73 million.

Operating Cash Flow	-36.33M
Capital Expenditures	-1.40M
Free Cash Flow	-37.73M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Abeona Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-92.79%
Shareholder Yield	-92.79%
Earnings Yield	-27.35%
FCF Yield	-19.47%

Stock Splits

The last stock split was on July 5, 2022. It was a reverse split with a ratio of 0.04.

Last Split Date	Jul 5, 2022
Split Type	Reverse
Split Ratio	0.04

Scores

Abeona Therapeutics has an Altman Z-Score of -8.72. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-8.72
Piotroski F-Score	n/a